SNY
Sanofi NASDAQ Listed Jul 1, 2002$42.38
-0.28%
vs $42.50
Mkt Cap $103.4B
52w Low $42.37
0.1% of range
52w High $52.34
50d MA $44.75
200d MA $47.14
P/E (TTM)
20.9x
EV/EBITDA
8.8x
P/B
1.4x
Debt/Equity
0.3x
ROE
—
P/FCF
11.6x
RSI (14)
43.60
ATR (14)
$0.61
Beta
0.32
50d MA
$44.75
200d MA
$47.14
Avg Volume
2.8M
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
54, Rue La BoEtie · Paris, I0 75008 · FR
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | 1.06 | 1.10 | +3.8% | 47.53 | -0.3% | -1.6% | -1.9% | +0.1% | +0.2% | +1.2% | — |
| Jan 29, 2026 | AMC | 0.84 | 0.89 | +6.0% | 46.20 | +1.5% | +1.8% | +0.5% | +0.5% | +1.2% | -1.2% | — |
| Oct 24, 2025 | AMC | 1.60 | 1.70 | +6.2% | 51.64 | -0.5% | -0.4% | -0.7% | -0.7% | +0.5% | -0.7% | — |
| Jul 31, 2025 | AMC | 0.96 | 0.90 | -6.2% | 45.64 | +0.7% | +2.4% | +2.8% | -0.4% | -3.5% | +2.7% | — |
| Apr 24, 2025 | AMC | 0.90 | 0.94 | +4.4% | 53.54 | -1.3% | -2.3% | +0.8% | +1.8% | +2.3% | -1.5% | — |
| Jan 30, 2025 | AMC | 0.71 | 0.70 | -1.4% | 54.15 | +0.0% | +0.4% | -1.8% | +0.3% | +0.0% | -1.2% | — |
| Oct 25, 2024 | AMC | 1.35 | 1.57 | +16.3% | 54.34 | -0.3% | +0.0% | -1.0% | -0.7% | -1.1% | +0.7% | — |
| Jul 25, 2024 | AMC | 0.86 | 0.93 | +8.1% | 53.10 | -0.8% | -1.3% | -0.6% | -0.8% | +0.2% | -0.3% | — |
| Apr 25, 2024 | AMC | 0.94 | 0.97 | +3.2% | 49.36 | -1.1% | -0.5% | -0.1% | +0.3% | +1.6% | -1.1% | — |
| Feb 1, 2024 | AMC | 0.94 | 0.89 | -5.3% | 48.41 | -0.8% | -2.4% | -0.6% | +0.2% | -0.3% | -0.8% | — |
| Oct 27, 2023 | AMC | 1.37 | 1.39 | +1.5% | 43.13 | +2.9% | +4.0% | +0.9% | +2.4% | +0.4% | -1.5% | — |
| Jul 28, 2023 | AMC | 1.55 | 0.95 | -38.7% | 52.48 | +2.3% | +1.7% | -0.6% | -3.0% | -1.0% | +1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16 | UBS | Downgrade | Buy → Neutral | — | $47.47 | $46.93 | -1.1% | -1.9% | -1.8% | +1.0% | +0.7% | +1.5% |
| Jan 6 | Barclays | Downgrade | Overweight → Equal Weight | — | $47.51 | $48.13 | +1.3% | +1.4% | +0.4% | -0.5% | +1.9% | -2.9% |
| Dec 9 | Guggenheim | Downgrade | Buy → Neutral | — | $48.44 | $48.15 | -0.6% | -1.3% | +0.9% | +1.2% | -0.4% | -1.8% |
| Dec 8 | JP Morgan | Downgrade | Overweight → Neutral | — | $49.53 | $48.65 | -1.8% | -2.2% | -1.3% | +0.9% | +1.2% | -0.4% |
| Sep 8 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $46.50 | $46.61 | +0.2% | +0.6% | +1.4% | -0.6% | +1.0% | -1.3% |
| Sep 2 | Deutsche Bank | Upgrade | Hold → Buy | — | $49.48 | $49.67 | +0.4% | +0.2% | +0.6% | -9.1% | +2.6% | +0.6% |
| Aug 8 | JP Morgan | Upgrade | Neutral → Overweight | — | $47.43 | $46.89 | -1.1% | -0.6% | +0.2% | +1.8% | +1.4% | +0.6% |
| Jul 26 | Argus | Maintains | Buy → Buy | — | $53.10 | $52.67 | -0.8% | -1.3% | -0.6% | -0.8% | +0.2% | -0.3% |
| Mar 27 | Argus | Maintains | Buy → Buy | — | $52.61 | $53.00 | +0.7% | +1.2% | +1.8% | +0.5% | -0.9% | +0.8% |
| Aug 12 | Deutsche Bank | Upgrade | Sell → Hold | — | $43.42 | $43.97 | +1.3% | +2.2% | -1.2% | +2.2% | -5.9% | -2.3% |
| Sep 27 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $47.94 | $48.30 | +0.8% | +0.4% | -0.5% | +1.0% | -0.3% | -0.6% |
| Mar 11 | Goldman Sachs | Upgrade | Neutral → Buy | — | $46.16 | $45.21 | -2.1% | -3.0% | -8.8% | +7.0% | -5.0% | +5.0% |
| Feb 19 | Argus | Maintains | Buy → Buy | — | $51.14 | $50.87 | -0.5% | -0.8% | +0.1% | +0.2% | -2.0% | -1.7% |
| Jan 6 | JP Morgan | Upgrade | Neutral → Overweight | — | $50.76 | $50.87 | +0.2% | +1.0% | -1.0% | +0.5% | +0.4% | +0.9% |
| Dec 6 | Barclays | Downgrade | Equal Weight → Underweight | — | $46.08 | $46.31 | +0.5% | -0.1% | -1.6% | +6.2% | +1.9% | +1.0% |
| Sep 23 | Guggenheim | Upgrade | Neutral → Buy | — | $46.46 | $45.95 | -1.1% | -0.5% | +0.9% | -0.3% | +0.3% | -0.8% |
| Nov 8 | Argus | Maintains | Buy → Buy | — | $45.33 | $45.18 | -0.3% | -0.8% | +1.4% | -2.1% | +0.7% | +0.4% |
| Nov 1 | Barclays | Upgrade | Underweight → Equal Weight | — | $44.72 | $45.10 | +0.8% | +0.9% | -2.1% | +1.4% | -0.4% | +1.6% |
| Sep 10 | BofA Securities | Upgrade | Neutral → Buy | — | $42.09 | $42.74 | +1.5% | +1.3% | -0.4% | +2.0% | +2.4% | -1.3% |
| Aug 24 | Argus | Maintains | Buy → Buy | — | $43.07 | $43.22 | +0.3% | +1.2% | -0.2% | +0.3% | +0.7% | -0.9% |
| Aug 10 | Citigroup | Upgrade | Neutral → Buy | — | $41.92 | $42.36 | +1.0% | -0.8% | -0.1% | -0.5% | -2.2% | +2.1% |
| Jan 23 | Barclays | Downgrade | Equal Weight → Underweight | — | $43.20 | $44.08 | +2.0% | +1.2% | +1.9% | +1.0% | +1.7% | -1.0% |
| Nov 15 | Barclays | Upgrade | Underweight → Equal Weight | — | $44.65 | $44.47 | -0.4% | +0.0% | -0.0% | -0.2% | -0.5% | +1.1% |
| Aug 30 | HSBC | Upgrade | Reduce → Hold | — | $48.96 | $48.44 | -1.1% | -1.6% | +1.3% | +1.0% | -1.0% | +1.2% |
| May 12 | Barclays | Upgrade | Equal Weight → Overweight | — | $39.56 | $40.09 | +1.3% | -0.8% | -0.2% | +1.4% | -0.6% | -0.1% |
| May 3 | HSBC | Downgrade | Buy → Hold | — | $41.46 | $41.38 | -0.2% | -0.7% | -1.9% | -3.2% | -0.3% | +1.3% |
| Dec 10 | Exane BNP Paribas | Downgrade | Neutral → Underperform | — | $42.24 | $41.95 | -0.7% | -0.9% | +0.0% | -0.8% | +3.4% | +1.6% |
| Dec 1 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $44.22 | $44.51 | +0.7% | -0.4% | -0.4% | -1.7% | +0.5% | +0.0% |
| Nov 9 | Bryan Garnier | Downgrade | Buy → Neutral | — | $46.60 | $45.52 | -2.3% | -2.5% | -1.1% | +0.2% | -3.1% | -1.5% |
| Nov 9 | Bernstein | Downgrade | Outperform → Market Perform | — | $46.60 | $45.52 | -2.3% | -2.5% | -1.1% | +0.2% | -3.1% | -1.5% |
| Mar 17 | Leerink Swann | Upgrade | Market Perform → Outperform | — | $48.62 | $48.71 | +0.2% | +0.7% | +2.5% | -1.5% | +2.4% | +0.7% |
| Oct 29 | BofA Securities | Downgrade | Buy → Neutral | — | $48.07 | $45.37 | -5.6% | -5.9% | +1.1% | +1.2% | -1.0% | -0.6% |
| Oct 29 | Deutsche Bank | Downgrade | Buy → Hold | — | $48.07 | $45.37 | -5.6% | -5.9% | +1.1% | +1.2% | -1.0% | -0.6% |
| Oct 29 | Jefferies | Downgrade | Buy → Hold | — | $48.07 | $45.37 | -5.6% | -5.9% | +1.1% | +1.2% | -1.0% | -0.6% |
| Oct 29 | Barclays | Downgrade | Overweight → Equal Weight | — | $48.07 | $45.37 | -5.6% | -5.9% | +1.1% | +1.2% | -1.0% | -0.6% |
| Oct 28 | Deutsche Bank | Downgrade | Buy → Hold | — | $52.82 | $48.22 | -8.7% | -9.0% | -5.9% | +1.1% | +1.2% | -1.0% |
| Jan 23 | Citigroup | Downgrade | Buy → Neutral | — | $51.53 | $51.86 | +0.6% | -1.4% | -3.1% | +0.2% | +0.2% | -1.0% |
| Jan 9 | S&P Capital IQ | Downgrade | Buy → Hold | — | $51.08 | $50.99 | -0.2% | -0.5% | -0.0% | -1.5% | +1.5% | +0.7% |
| Jan 6 | JP Morgan | Downgrade | Overweight → Neutral | — | $52.04 | $52.07 | +0.1% | -0.1% | -0.2% | -1.6% | -0.5% | -0.0% |
| Nov 18 | Kepler Cheuvreux | Upgrade | Hold → Buy | — | $53.96 | $54.40 | +0.8% | +0.1% | -1.3% | -0.7% | -0.6% | +0.8% |
| Nov 15 | Mirabaud | Upgrade | Neutral → Buy | — | $53.05 | $53.64 | +1.1% | +1.7% | +0.1% | -1.3% | -0.7% | -0.6% |
| Nov 15 | Mirabaud Securities | Upgrade | Neutral → Buy | — | $53.05 | $53.64 | +1.1% | +1.7% | +0.1% | -1.3% | -0.7% | -0.6% |
| Oct 31 | Natixis | Upgrade | Neutral → Buy | — | $52.81 | $53.73 | +1.7% | +1.3% | -1.5% | +0.4% | -0.2% | +1.2% |
| Oct 18 | Leerink Swann | Downgrade | Outperform → Market Perform | — | $50.13 | $49.94 | -0.4% | +0.2% | +0.7% | +1.5% | -0.2% | +0.6% |
| Sep 16 | Barclays | Upgrade | Equal Weight → Overweight | — | $47.96 | $48.44 | +1.0% | -0.0% | +2.7% | +2.4% | +0.8% | +0.4% |
| Aug 21 | TD Cowen | Downgrade | Outperform → Market Perform | — | $51.75 | $51.23 | -1.0% | -3.0% | +0.1% | +0.5% | +0.6% | -2.5% |
| May 3 | Banco Sabadell | Downgrade | Buy → Sell | — | $55.00 | $55.32 | +0.6% | +1.2% | -4.7% | +1.1% | +2.2% | -0.9% |
| Feb 8 | Kepler Cheuvreux | Downgrade | Buy → Hold | — | $45.30 | $45.53 | +0.5% | +2.7% | +3.2% | +1.7% | +1.5% | -2.6% |
| Jan 29 | Barclays | Downgrade | Overweight → Equal Weight | — | $48.92 | $48.70 | -0.4% | -0.2% | +0.5% | -0.8% | +1.3% | -4.0% |
| Jan 28 | Goldman Sachs | Upgrade | Sell → Neutral | — | $49.28 | $49.45 | +0.3% | -0.7% | -0.2% | +0.5% | -0.8% | +1.3% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Dodge & Cox | 29,504,632 | $1.4B | Reduced | Mar 2026 |
| 2 | Morgan Stanley | 18,204,392 | $882M | Added | Dec 2025 |
| 3 | Bank Of America Corp /de/ | 9,484,350 | $457M | Reduced | Mar 2026 |
| 4 | Franklin Resources Inc | 7,165,193 | $345M | Added | Mar 2026 |
| 5 | Invesco Ltd. | 6,621,539 | $319M | Added | Mar 2026 |
| 6 | Barrow Hanley Mewhinney & Strauss Llc | 5,887,466 | $284M | Reduced | Mar 2026 |
| 7 | Jpmorgan Chase & Co | 5,600,731 | $262M | Added | Mar 2026 |
| 8 | Mondrian Investment Partners Ltd | 5,040,065 | $243M | Added | Mar 2026 |
| 9 | Fmr Llc | 4,010,161 | $193M | Added | Mar 2026 |
| 10 | Raymond James Financial Inc | 3,812,745 | $184M | Added | Mar 2026 |
| 11 | Boston Partners | 3,599,284 | $173M | Reduced | Mar 2026 |
| 12 | Millennium Management | 3,440,654 | $166M | Added | Mar 2026 |
| 13 | Wells Fargo & Company/mn | 3,415,115 | $165M | New | Mar 2026 |
| 14 | Royal Bank Of Canada | 3,155,080 | $152M | Added | Mar 2026 |
| 15 | Equity Investment Corp | 2,663,054 | $128M | Added | Mar 2026 |
| 16 | Barclays Plc | 2,356,559 | $114M | Added | Mar 2026 |
| 17 | Alyeska Investment Group, L.p. | 2,306,229 | $111M | New | Mar 2026 |
| 18 | Northern Trust Corp | 2,277,939 | $110M | Added | Mar 2026 |
| 19 | Nuveen, Llc | 1,911,226 | $92M | Added | Mar 2026 |
| 20 | Victory Capital Management Inc | 1,830,115 | $88M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$103.44B
Enterprise Value
$111.49B
P/E (TTM)
20.88x
Forward P/E
10.07x
PEG Ratio
-1.66x
P/B
1.44x
P/S
2.21x
P/FCF
11.63x
EV/EBITDA
8.79x
Shares Out
2.44B
Financials (TTM)
Revenue
$46.72B
Net Income
$7.81B
EBITDA
$12.68B
Free Cash Flow
$8.89B
Op Cash Flow
$10.75B
EPS Basic
$2.03
EPS Diluted
$2.03
EPS Forward
$4.21
Gross Margin
72.3%
Op Margin
13.6%
Net Margin
16.7%
Balance Sheet
Total Assets
$126.81B
Total Liab.
$55.10B
Total Equity
$71.71B
Cash
$7.66B
LT Debt
$15.71B
Book Value/Sh
$29.38
Debt/Equity
0.31x
Current Ratio
1.09
Quick Ratio
0.29
Returns & Growth
ROE
—
ROA
—
ROIC
5.1%
Rev Growth YoY
+5.5%
EPS Growth YoY
-7.7%
Price Returns
2W
+1.9%
1M
-6.2%
3M
-10.3%
6M
-12.4%
12M
-11.5%
Technicals
52W High
$52.34
52W Low
$42.37
50d MA
$44.75
200d MA
$47.14
RSI (14)
43.60
ATR (14)
$0.61
Beta
0.32
Avg Volume
2.8M
Dividends
Div Rate
$1.88
Div Yield
4.1%
Frequency
1
Ex-Div Date
May 4, 2026
Analyst Price Targets
Consensus
$50.00
High
$50.00
Low
$50.00
Median
$50.00
Data updated apr 27, 2026 2:17am
· Source: financialmodelingprep.com